BioCentury | Feb 15, 2017
Distillery Therapeutics

Hepatic

...Mouse studies suggest inhibiting CELF1 could help treat liver fibrosis. In patient liver tissue samples, CELF1...
...cells decreased liver fibrosis compared with normal CELF1 expression. Also in the mouse model, the CELF1...
...Next steps could include testing the compound in additional liver fibrosis models. TARGET/MARKER/PATHWAY: CUGBP Elav-like family member 1 (CELF1; CUGBP1...
BioCentury | Mar 14, 2016
Emerging Company Profile

AMO's CNS ammunition

...repeats increase GSK3B activity, leading to muscle weakness caused by increased levels of CUGBP Elav-like family member 1 (CELF1; CUGBP1...
BioCentury | Dec 3, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

...information Cardiovascular disease Cardiomyopathy associated with muscular dystrophy CUG triplet repeat, RNA binding protein 1 (CUGBP1...
...dystrophy type 1 (DM1). In a mouse model of cardiac-specific DM1, a PKC inhibitor decreased CUGBP1...
Items per page:
1 - 3 of 3